Cargando…

Identification of Molecular Signatures and Candidate Drugs in Vascular Dementia by Bioinformatics Analyses

Vascular dementia (VaD) is considered to be the second most common form of dementia after Alzheimer’s disease, and no specific drugs have been approved for VaD treatment. We aimed to identify shared transcriptomic signatures between the frontal cortex and temporal cortex in VaD by bioinformatics ana...

Descripción completa

Detalles Bibliográficos
Autores principales: Shu, Jun, Wei, Wenshi, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873373/
https://www.ncbi.nlm.nih.gov/pubmed/35221911
http://dx.doi.org/10.3389/fnmol.2022.751044
_version_ 1784657450623827968
author Shu, Jun
Wei, Wenshi
Zhang, Li
author_facet Shu, Jun
Wei, Wenshi
Zhang, Li
author_sort Shu, Jun
collection PubMed
description Vascular dementia (VaD) is considered to be the second most common form of dementia after Alzheimer’s disease, and no specific drugs have been approved for VaD treatment. We aimed to identify shared transcriptomic signatures between the frontal cortex and temporal cortex in VaD by bioinformatics analyses. Gene ontology and pathway enrichment analyses, protein–protein interaction (PPI) and hub gene identification, hub gene–transcription factor interaction, hub gene–microRNA interaction, and hub gene–drug interaction analyses were performed. We identified 159 overlapping differentially expressed genes (DEGs) between the frontal cortex and temporal cortex that were enriched mainly in inflammation and innate immunity, synapse pruning, regeneration, positive regulation of angiogenesis, response to nutrient levels, and positive regulation of the digestive system process. We identified 10 hub genes in the PPI network (GNG13, CD163, C1QA, TLR2, SST, C1QB, ITGB2, CCR5, CRH, and TAC1), four central regulatory transcription factors (FOXC1, CREB1, GATA2, and HINFP), and four microRNAs (miR-27a-3p, miR-146a-5p, miR-335-5p, and miR-129-2-3p). Hub gene–drug interaction analysis found four drugs (maraviroc, cenicriviroc, PF-04634817, and efalizumab) that could be potential drugs for VaD treatment. Together, our results may contribute to understanding the underlying mechanisms in VaD and provide potential targets and drugs for therapeutic intervention.
format Online
Article
Text
id pubmed-8873373
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88733732022-02-26 Identification of Molecular Signatures and Candidate Drugs in Vascular Dementia by Bioinformatics Analyses Shu, Jun Wei, Wenshi Zhang, Li Front Mol Neurosci Molecular Neuroscience Vascular dementia (VaD) is considered to be the second most common form of dementia after Alzheimer’s disease, and no specific drugs have been approved for VaD treatment. We aimed to identify shared transcriptomic signatures between the frontal cortex and temporal cortex in VaD by bioinformatics analyses. Gene ontology and pathway enrichment analyses, protein–protein interaction (PPI) and hub gene identification, hub gene–transcription factor interaction, hub gene–microRNA interaction, and hub gene–drug interaction analyses were performed. We identified 159 overlapping differentially expressed genes (DEGs) between the frontal cortex and temporal cortex that were enriched mainly in inflammation and innate immunity, synapse pruning, regeneration, positive regulation of angiogenesis, response to nutrient levels, and positive regulation of the digestive system process. We identified 10 hub genes in the PPI network (GNG13, CD163, C1QA, TLR2, SST, C1QB, ITGB2, CCR5, CRH, and TAC1), four central regulatory transcription factors (FOXC1, CREB1, GATA2, and HINFP), and four microRNAs (miR-27a-3p, miR-146a-5p, miR-335-5p, and miR-129-2-3p). Hub gene–drug interaction analysis found four drugs (maraviroc, cenicriviroc, PF-04634817, and efalizumab) that could be potential drugs for VaD treatment. Together, our results may contribute to understanding the underlying mechanisms in VaD and provide potential targets and drugs for therapeutic intervention. Frontiers Media S.A. 2022-02-11 /pmc/articles/PMC8873373/ /pubmed/35221911 http://dx.doi.org/10.3389/fnmol.2022.751044 Text en Copyright © 2022 Shu, Wei and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Neuroscience
Shu, Jun
Wei, Wenshi
Zhang, Li
Identification of Molecular Signatures and Candidate Drugs in Vascular Dementia by Bioinformatics Analyses
title Identification of Molecular Signatures and Candidate Drugs in Vascular Dementia by Bioinformatics Analyses
title_full Identification of Molecular Signatures and Candidate Drugs in Vascular Dementia by Bioinformatics Analyses
title_fullStr Identification of Molecular Signatures and Candidate Drugs in Vascular Dementia by Bioinformatics Analyses
title_full_unstemmed Identification of Molecular Signatures and Candidate Drugs in Vascular Dementia by Bioinformatics Analyses
title_short Identification of Molecular Signatures and Candidate Drugs in Vascular Dementia by Bioinformatics Analyses
title_sort identification of molecular signatures and candidate drugs in vascular dementia by bioinformatics analyses
topic Molecular Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873373/
https://www.ncbi.nlm.nih.gov/pubmed/35221911
http://dx.doi.org/10.3389/fnmol.2022.751044
work_keys_str_mv AT shujun identificationofmolecularsignaturesandcandidatedrugsinvasculardementiabybioinformaticsanalyses
AT weiwenshi identificationofmolecularsignaturesandcandidatedrugsinvasculardementiabybioinformaticsanalyses
AT zhangli identificationofmolecularsignaturesandcandidatedrugsinvasculardementiabybioinformaticsanalyses